



# MEDICARE FORM

## Viscosupplementation Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Virginia (HMO D-SNP):  
FAX: 1-833-280-5224  
PHONE: 1-855-463-0933

For other lines of business:  
Please use other form.

Note: Durolane, Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Monovisc, Supartz, and TriVisc are non-preferred. The preferred products are Gel-One, Orthovisc, Synvisc, Synvisc One, and Visco-3.

Please indicate:  Start of treatment: Start date \_\_\_\_ / \_\_\_\_ / \_\_\_\_  Continuation of therapy (Request Additional Series Below)

Precertification Requested By: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

### A. PATIENT INFORMATION

First Name:		Last Name:	
Address:		City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms	

### B. INSURANCE INFORMATION

Aetna Member ID #:	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #:	If yes, provide ID#: _____ Carrier Name: _____
Insured:	Insured: _____

### C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Office Contact Name:				Phone:	

### D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

<b>Place of Administration:</b> <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____	<b>Dispensing Provider/Pharmacy:</b> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other _____ Name: _____ Address: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	---

### E. PRODUCT INFORMATION

Request is for:  Euflexxa (1% sodium hyaluronate)  Durolane (hyaluronic acid)  Gel-One (cross-linked hyaluronate)  
 Gelsyn-3 (sodium hyaluronate)  GenVisc 850 (sodium hyaluronate)  Hyalgan (sodium hyaluronate)  Supartz FX (sodium hyaluronate)  
 Hymovis (high molecular weight viscoelastic hyaluronan)  Orthovisc (high molecular weight hyaluronan)  Monovisc (sodium hyaluronate)  
 Synvisc (hylan G-F 20)  Synvisc-One (hylan G-F 20)  TriVisc (sodium hyaluronate)  Visco-3 (sodium hyaluronate)  
 Synjojoynt (1% sodium hyaluronate)  Trilonon (1% sodium hyaluronate)

Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_ HCPCS Code: \_\_\_\_\_

### F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

### G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

**For All Requests (includes Medicare patient requests, clinical documentation required for all requests):**  
Note: Durolane, Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Monovisc, Supartz, TriVisc are non-preferred. The preferred products are Gel-One, Orthovisc, Synvisc, Synvisc One, and Visco-3.

Yes  No Has the patient had prior therapy with the requested viscosupplementation product within the last 365 days?  
 Yes  No Has the patient had an intolerance or contraindication to Gel-One, Orthovisc, Synvisc, Synvisc One, or Visco-3?  
Please explain if there are any other medical reason(s) that the patient cannot use Gel-One, Orthovisc, Synvisc, Synvisc One, or Visco-3  
\_\_\_\_\_  
\_\_\_\_\_  
 Yes  No Does the patient have documented symptomatic osteoarthritis (OA) of the tibiofemoral articulation of the knee?  
 > Which knee will the viscosupplement be used?  Left knee  Right knee  Both knees

Continued on next page



# MEDICARE FORM

## Viscosupplementation Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

Virginia (HMO D-SNP):  
FAX: 1-833-280-5224  
PHONE: 1-855-463-0933

For other lines of business:  
Please use other form.

Note: Durolane, Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Monovisc, Supartz, and TriVisc are non-preferred. The preferred products are Gel-One, Orthovisc, Synvisc, Synvisc One, and Visco-3.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

**G. CLINICAL INFORMATION (continued)** – Required clinical information must be completed in its entirety for all precertification requests.

Yes  No Is there radiologic evidence of osteoarthritis (OA) of the knee?  
 Yes  No Is the patient symptomatic?  
 Which of the following documented symptoms of osteoarthritis (OA) does the patient have? (Check ALL that apply)  
 Knee Pain  Bony enlargement  Bony tenderness  Crepitus (noisy, grating sound) on active motion  
 Erythrocyte sedimentation rate (ESR) less than 40 mm/hr  Less than 30 minutes of morning stiffness  
 No palpable warmth of synovium  Over 50 years of age  
 Rheumatoid factor less than 1:40 titer (agglutination method)  
 Synovial fluid signs (clear fluid of normal viscosity and WBC less than 2000/mm3)  
 Which of the following radiologic findings support the clinical diagnosis of osteoarthritis (OA)?  
 Please select:  Joint space narrowing  Subchondral sclerosis  Osteophytes and sub-chondral cysts  
 Yes  No Does the patient have knee pain that interferes with functional activities (e.g. ambulation or prolonged standing)?  
 Yes  No Can the knee pain be attributed to any other forms of joint disease (other than osteoarthritis)?  
 Yes  No Has the patient completed conservative therapy in each joint to be treated with viscosupplementation?  
 Yes  No Is the patient unable to tolerate conservative therapy because of adverse side effects?  
 Please indicate which of the following conservative therapies the patient completed:  
 Physical therapy  Acetaminophen  Topical capsaicin cream  NSAID's, Specify: \_\_\_\_\_  
 Other: please explain: \_\_\_\_\_  
 Yes  No Has the conservative treatment resulted in functional improvement after therapy?  
 Yes  No Has the patient failed to adequately respond to aspiration and injection of intra-articular steroids?  
 Yes  No Are there any contraindications to the patient receiving viscosupplementation injections (e.g. active joint infection, bleeding disorder or skin infections at the injection site)?  
 Yes  No Is the patient scheduled to undergo a total knee replacement within 6 months of starting viscosupplementation treatment?  
 Yes  No Will the drug requested be used concomitantly with any of the following?  
 Please select:  With intra-articular anesthetics  With intra-articular corticosteroids  With intra-articular platelet rich plasma  
 With intra-articular mannitol/sorbitol  With intra-articular mesenchymal stem cells  With another viscosupplement  
 Yes  No Does the patient have morning stiffness of less than 30 minutes in duration?  
 Yes  No Does the patient have crepitus on motion of the knee?

**For All Additional Series Requests (clinical documentation required for all requests):**

What product did the patient last receive? \_\_\_\_\_  
 Enter date of last injection from prior series: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Yes  No Have at least six months elapsed since the last injection in the prior series?  
 Yes  No Has the patient had a documented reduction in the dose of NSAID's, other anti-inflammatories, or other analgesics during the 6-month period following the previous injection series?  
 Yes  No Does the patient require NSAID's, other anti-inflammatories, or other analgesics for a comorbid medical condition in addition to OA of the knee? **If yes**, please identify the comorbid medical condition: \_\_\_\_\_  
 Yes  No  N/A Was there a reduction in the number of intra-articular steroid injections or aspirations during the 6-month period following the series?  
 Yes  No Is there objective documentation to support significant improvement of functional capacity as a result of previous injection series?  
 Yes  No Is there objective documentation to support significant improvement in pain as a result of previous injections?

**H. ACKNOWLEDGEMENT**

Request Completed By (Signature Required): \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.